Gilead withdraws bladder cancer drug in US
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high NSCLC. Started in February 2023, the trial currently bears a primary completion date in January 2027.
Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
NC Insurance Commissioner Mike Causey honors 7 veteran Mount Gilead firefighters during the department's 100-year celebration ...
Zacks.com on MSN2d
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...
Fintel on MSN1d
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
Mount Gilead, NC, celebrates the 100th anniversary of its fire department, honoring seven firefighters for a combined 244 ...
Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback